Lates News

After the next-generation weight-loss drug CagriSema from Novo Nordisk failed to meet the key target of proving its effectiveness is not inferior to the competitor drug Victoza from Novo Nordisk, the company's stock plummeted by 14.5% in pre-market trading in the United States. Victoza is the active ingredient in Novo Nordisk's flagship drugs Mounjaro and Zepbound.